Scientific article

Quels espoirs pour l'hépatite delta ?

Published inRevue médicale suisse, vol. 12, no. 528, p. 1415-1418
Publication date2016

Hepatitis D or delta is a chronic liver disease globally reaching 15‑20M people. Its agent, hepatitis D virus (HDV) requires the presence of hepatitis B virus (HBV) to complete its life cycle. It represents one of the most severe forms of viral hepatitis. Current therapy with pegylated interferon alpha leads to viral eradication only in 25 % of cases. New treatments targeting the virus life cycle are sought. For example Myrcludex-B, which inhibits the entry into hepatocytes, lonafarnib which prevents the assemblage of the viral particle and the molecule REP 2139 which, among other unclear mechanisms, impedes the exit of the virus. This allows considering a better management of a condition for which there is currently no satisfactory treatment.

Citation (ISO format)
GUGLIELMI, Stefano, FROSSARD, Jean-Louis, NEGRO, Francesco. Quels espoirs pour l’hépatite delta ? In: Revue médicale suisse, 2016, vol. 12, n° 528, p. 1415–1418.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation09/12/2017 10:42:00 AM
First validation09/12/2017 10:42:00 AM
Update time03/15/2023 2:14:10 AM
Status update03/15/2023 2:14:09 AM
Last indexation01/17/2024 1:09:31 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack